Acorda Therapeutics Inc  

(Public, NASDAQ:ACOR)   Watch this stock  
Find more results for ACOR
-0.10 (-0.40%)
Feb 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 24.35 - 25.15
52 week 16.40 - 37.36
Open 24.90
Vol / Avg. 416,167.00/840,799.00
Mkt cap 1.14B
P/E     -
Div/yield     -
EPS -0.76
Shares 46.13M
Beta 1.53
Inst. own 105%
Feb 9, 2017
Q4 2016 Acorda Therapeutics Inc Earnings Release (Estimated)
Jan 9, 2017
Acorda Therapeutics Inc at JPMorgan Healthcare Conference
Nov 29, 2016
Acorda Therapeutics Inc at Piper Jaffray Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -2.20% -6.85%
Operating margin 0.51% -6.92%
EBITD margin - -3.55%
Return on average assets -0.93% -2.90%
Return on average equity -1.86% -5.46%
Employees 535 -
CDP Score - -


420 Saw Mill River Rd
ARDSLEY, NY 10502-2605
United States - Map
+1-914-3474300 (Phone)
+1-914-3474560 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza. Its research and development programs include CVT-301, Dalfampridine, Plumiaz, Neuregulin Program, Remyelinating Antibodies Program, CVT-427 and Chondroitinase Program. Its Ampyra is an oral drug for the treatment to improve walking in patients with multiple sclerosis. Zanaflex Capsules and tablets are used as short-acting drugs for the management of spasticity. Qutenza is a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. Its pipeline of neurological therapies addresses a range of disorders, including Parkinson's disease, chronic post-stroke walking deficits and migraine.

Officers and directors

Ron Cohen M.D. President,Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
David Lawrence Chief Business Operations, Principal Accounting Officer
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Andrew R. Blight Ph.D. Chief Scientific Officer
Age: 64
Bio & Compensation  - Reuters
Jane Wasman J.D. President - International, General Counsel, Corporate Secretary
Age: 60
Bio & Compensation  - Reuters
Burkhard Blank M.D. Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Andrew Hindman Chief Business Development Officer
Age: 44
Bio & Compensation  - Reuters
Lauren M. Sabella Chief Commercial Officer
Age: 54
Bio & Compensation  - Reuters
Catherine D. Strader Director
Bio & Compensation  - Reuters
Barry E. Greene Independent Director
Age: 52
Bio & Compensation  - Reuters
Peder K. Jensen M.D. Independent Director
Age: 61
Bio & Compensation  - Reuters